VTRS Viatris
Q3 2025 10-Q
Viatris (VTRS) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Management Discussion & Analysis
- • Revenue $3.76B Q3 2025, flat YoY ($3.75B Q3 2024); 9-month revenue $10.60B down 5% YoY ($11.21B 2024)
- • Gross margin decreased to 36% Q3 2025 from 39% Q3 2024; 9-month margin 36% vs 39% YoY due to Indore facility impact
Risk Factors
- • New risk: Potential tariffs up to 15% on brand pharmaceuticals from EU due to new bilateral trade agreements
- • Material update: Increased cost of goods and supply chain disruptions from proposed tariffs on pharmaceutical imports and APIs
Quarterly Financial SummaryXBRL
Revenue
$3.7B
Net Income
-$128M
Net Margin
-3.4%
Source: XBRL data from Viatris Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Viatris Quarterly Reports
Get deeper insights on Viatris
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.